AI Medical Compendium Journal:
The lancet. Healthy longevity

Showing 1 to 5 of 5 articles

Application of a deep-learning marker for morbidity and mortality prediction derived from retinal photographs: a cohort development and validation study.

The lancet. Healthy longevity
BACKGROUND: Biological ageing markers are useful to risk stratify morbidity and mortality more precisely than chronological age. In this study, we aimed to develop a novel deep-learning-based biological ageing marker (referred to as RetiPhenoAge here...

ExplaiNAble BioLogical Age (ENABL Age): an artificial intelligence framework for interpretable biological age.

The lancet. Healthy longevity
BACKGROUND: Biological age is a measure of health that offers insights into ageing. The existing age clocks, although valuable, often trade off accuracy and interpretability. We introduce ExplaiNAble BioLogical Age (ENABL Age), a computational framew...

Chest radiography as a biomarker of ageing: artificial intelligence-based, multi-institutional model development and validation in Japan.

The lancet. Healthy longevity
BACKGROUND: Chest radiographs are widely available and cost-effective; however, their usefulness as a biomarker of ageing using multi-institutional data remains underexplored. The aim of this study was to develop a biomarker of ageing from chest radi...

Artificial intelligence for older people receiving long-term care: a systematic review of acceptability and effectiveness studies.

The lancet. Healthy longevity
Artificial intelligence (AI)-enhanced interventions show promise for improving the delivery of long-term care (LTC) services for older people. However, the research field is developmental and has yet to be systematically synthesised. This systematic ...

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.

The lancet. Healthy longevity
BACKGROUND: In Japan, docetaxel, a cytotoxic monotherapy, is the standard drug administered to older patients with advanced non-small-cell lung cancer (NSCLC). Carboplatin plus nab-paclitaxel has shown a high objective response rate in patients with ...